What they were paid
LIGAND PHARMACEUTICALS Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | — | — | — | $0 | — |
| FY2024 | $47,065 | $100,235 | $192,613 | — | $339,913 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LIGAND PHARMACEUTICALS INC DEF 14A filed April 21, 2026, accession 0000886163-26-000021, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025LIGAND PHARMACEUTICALS pays directors a $42,000 cash retainer and $375,000 in RSUs and Options.
Committees
FY2025 · as the proxy prints themAudit
The rest of the LIGAND PHARMACEUTICALS board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Jason Haas | Independent Director | $458,069 |
| Jason M. Aryeh | Independent Director | $450,569 |
| John L. LaMattina | Independent Director | $440,569 |
| John W. Kozarich | Independent Director | $473,069 |
| Nancy R. Gray | Independent Director | $448,069 |
| Stephen L. Sabba | Independent Director | $453,069 |
| Todd C. Davis | Director | $0 |
The full LIGAND PHARMACEUTICALS compensation record
free company briefThis page is one director within LIGAND PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat